ClinicalTrials.gg
Active, not recruitingNCT02434809Updated May 6, 2026

Respiratory Motion-Corrected Cone-Beam CT and Intratreatment Gating Based on Electromagnetic Transponders to Reduce Target Position Uncertainty in Radiation Treatment of Lung Malignancies

An interventional study of Bronchoscopic Implantation and Cone-Beam CT-Guided in Lung Cancer, sponsored by Memorial Sloan Kettering Cancer Center. Active, not recruiting at 3 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-06.

Sponsored by Memorial Sloan Kettering Cancer Center · Not applicable, Interventional, and Diagnostic

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
17
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 108 studies in Lung Neoplasms by Memorial Sloan Kettering Cancer Center — 9 open to participants now, 20 under way, none of them phase 3. Lung Neoplasms · Memorial Sloan Kettering Cancer Center.

Enrollment
50th of 62
17 · median 48
Started
2015
with 6 others
No phase
16 of 108
3 open now
Primary completion
2027-04
later than 5 of 19 live
Registered
80th of 108
by date

Among the 108 studies in Lung Neoplasms by Memorial Sloan Kettering Cancer Center, this one is the 50th largest by enrollment of the 62 interventional ones that give a count, is one of 7 that started in 2015, is one of 16 with no phase, reaches primary completion later than 5 of the 19 other live ones, and was the 80th registered.

Lung Neoplasms

5,436 studies on the registry are indexed under Lung Neoplasms; 1,350 are open to participants now.

Browse Lung Neoplasms studies →

Open to participants now

9 of the 108 studies in Lung Neoplasms by Memorial Sloan Kettering Cancer Center are open now, in 2 countries. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 9 open studies →

Where they have run

Who these studies take

Of the 997 Lung Neoplasms studies recruiting now, 686 (69%) set no upper age limit and 143 (14%) stop at 75 or younger; 45 take children under 18; 143 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 108 studies in Lung Neoplasms by Memorial Sloan Kettering Cancer Center, or all of them as a file.
02

Study summary

The first purpose of this study is to test a new computer program that reduces the blurring in the cone-beam CT scan and helps the doctor to better locate the tumor. The investigators want to find out what effects, good and/or bad, that this has on the patient and the way we treat the cancer in the lungs.

The second purpose of this study is to test how well this computer program tracks markers in the images, compared to using radio signals to follow the markers.

03

Conditions studied

  • Lung Cancer

Browse trials for

Keywords

  • Respiratory Motion-Corrected Cone-Beam CT
  • Radiation
  • 14-225
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  • Histologic proof of suitable for thoracic radiation therapy
  • Patient is planning to undergo radiation therapy for primary or recurrent malignancies of the lung or malignancies to the lung.
  • Age ≥ 18 years old
  • Performance Status ≥ 60%
  • At least part of the tumor must be visible as observed in a diagnostic or planning CT.
  • Able to have bronchoscopic placement of Calypso transponders as confirmed on a recent (within the past 8 weeks) CT scan.

Exclusion Criteria:

  • Patients with active infections.
  • Bronchiectasis in the region of the intended implantation.
  • History of to nickel.
  • Other medical condition or laboratory value that would, at the discretion of the investigator, preclude the patient from participation in this clinical study.
  • Deemed unable to safely undergo or tolerate flexible bronchoscopy as per institutional guidelines
  • Unable to tolerate anesthesia or sedation
  • Enrolled in any other clinical studies the investigator believes to be in conflict with this investigation.
  • Female patients who are pregnant or nursing

Exclusion criteria for Calypso transponders:

  • Implants in the chest region that contain metal or conductive materials (e.g., metal implants, rods, or plates) which Calypso Medical considers will interfere with the Calypso System's electromagnetic localization.
  • Active implanted devices, such as pacemakers, defibrillators, and drug infusion pumps since the effects of the Calypso System operation on these devices are unknown.
  • Patients whose lung tumors are being monitored by MR imaging as part of standard clinical care. Implantation of transponders will degrade MR images.
  • Posterior lesions that would be >19 cm distance from Calypso detector plate.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
17 participants (actual)

Study arms

  • Experimental
    Patients with lung cancer

    Physician evaluation of patient setup accuracy will be performed using all available images and adjustments will be made as per standard practice. In addition, a respiration motion-corrected CBCT (daily for SBRT, weekly for standard fractionation) will be used to confirm the accuracy of Calypso-based setup. Patients will return for follow up at 3,6, 9, 12, 15, 18, 21 and 24 months (+/- 4 weeks) following completion of radiation therapy. The following assessments will be performed at these visits: history and physical exam, diagnostic CT chest, and toxicity assessment.

    Procedure: Bronchoscopic Implantation · Device: Cone-Beam CT-Guided · Radiation: stereotactic body radiation treatments

Interventions

  • ProcedureBronchoscopic Implantation

    Calypso transponders

  • DeviceCone-Beam CT-Guided
  • Radiationstereotactic body radiation treatments
06

What researchers measure

Primary outcomes

  1. successful Calypso transponder implantation

    The RapidTrack algorithm will be considered successful if the centroid position of the Calypso transponders, as determined by the RapidTrack algorithm, are within 2 mm of the positions determined by the Calypso system 95% of the time.

    Time frame: 1 year

07

Study locations

3 sites
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2015, a primary completion of Apr 2027 and a completion of Apr 2027. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 30, 2015
First posted
May 5, 2015
Start
Apr 2015
Primary completionEst.
Apr 2027
CompletionEst.
Apr 2027
Last update
May 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02434809
Responsible party
Sponsor
First posted
May 5, 2015
Start date
Apr 2015
Primary completion
Apr 2027 (estimated)
Completion
Apr 2027 (estimated)
Last update
May 6, 2026

Study contacts

Zhang Peng, PhD
principal investigator · Memorial Sloan Kettering Cancer Center

Oversight

FDA-regulated drug
Yes
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion